Cyclin-dependent kinase-5 and p35/p25 activators in schizophrenia and major depression prefrontal cortex: Basal contents and effects of psychotropic medications

International Journal of Neuropsychopharmacology

Volumn 16, Issue 3, 2013, Pages 683-689

  Ramos Miguel, Alfredo ^a   Javier Meana, J ^b   García Sevilla, Jesús A ^a  

^a UNIVERSITAT DE LES ILLES BALEARS   (Spain)

^b UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

Antidepressants; antipsychotics; CDK5 p35 p25; major depression; schizophrenia

Indexed keywords

ANTIDEPRESSANT AGENT; CYCLIN DEPENDENT KINASE 5; MUNC18 1A; MUNC18 PROTEIN; PROTEIN P35; PSYCHOTROPIC AGENT; SYNTAXIN 1A; UNCLASSIFIED DRUG;

ARTICLE; BLOOD SAMPLING; DOWN REGULATION; HUMAN; MAJOR DEPRESSION; NEUROSECRETION; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN INTERACTION; SCHIZOPHRENIA; URINALYSIS;

ADULT; AGED; CYCLIN-DEPENDENT KINASE 5; DEPRESSIVE DISORDER, MAJOR; ENZYME ACTIVATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NERVE TISSUE PROTEINS; PREFRONTAL CORTEX; PSYCHOTROPIC DRUGS; RETROSPECTIVE STUDIES; SCHIZOPHRENIA;

EID: 84874624796     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145712000879     Document Type: Article

References (25)

1. Angelo M, Plattner F, Giese KP (2006). Cyclin-dependent kinase 5 in synaptic plasticity, learning and memory. Journal of Neurochemistry 99, 353-370. (Pubitemid 44477194)
2. Barnett DG, Bibb JA (2011). The role of Cdk5 in cognition and neuropsychiatric and neurological pathology. Brain Research Bulletin 85, 9-13.
3. Chergui K, Svenningsson P, Greengard P (2004). Cyclin-dependent kinase 5 regulates dopaminergic and glutamatergic transmission in the striatum. Proceedings of the National Academy of Sciences USA 101, 2191-2196. (Pubitemid 38229037)
4. Eastwood SL (2004). The synaptic pathology of schizophrenia : is aberrant neurodevelopment and plasticity to blame? International Review of Neurobiology 59, 47-72. (Pubitemid 39752411)
5. Engmann O, Hortoba?gyi T, Pidsley R, Troakes C, et al. (2011). Schizophrenia is associated with dysregulation of a Cdk5 activator that regulates synaptic protein expression and cognition. Brain 134, 2408-2421.
6. Ferrer-Alcon M, La Harpe R, Guimon J, Garca-Sevilla JA (2003). Downregulation of neuronal cdk5/p35 in opioid addicts and opiate-treated rats : relation to neurofilament phosphorylation. Neuropsychopharmacology 28, 947-955.
7. Fletcher AI, Shuang R, Giovannucci DR, Zhang L, et al. (1999). Regulation of exocytosis by cyclin-dependent kinase 5 via phosphorylation of Munc18. Journal of Biological Chemistry 274, 4027-4035.
8. Fung SJ, Sivagnanasundaram S, Weickert CS (2011). Lack of change in markers of presynaptic terminal abundance alongside subtle reductions in markers of presynaptic terminal plasticity in prefrontal cortex of schizophrenia patients. Biological Psychiatry 69, 71-19.
9. Funk AJ, McCullumsmith RE, Haroutunian V, Meador-Woodruff JH (2012). Abnormal activity of the MAPK-and cAMP-associated signaling pathways in frontal cortical areas in postmortem brain in schizophrenia. Neuropsychopharmacology 37, 896-905.
10. Garca-Fuster MJ, Ramos-Miguel A, Rivero G, La Harpe R, et al 2008 Regulation of the extrinsic and intrinsic apoptotic pathways in the prefrontal cortex of short-and long-term human opiate abusers. Neuroscience 157 105-119.
11. Gil-Pisa I, Munarriz-Cuezva E, Ramos-Miguel A, Urigu?en L, et al. (2012). Regulation of munc18-1 and syntaxin-1A interactive partners in schizophrenia prefrontal cortex : down-regulation of munc18-1a isoform and 75 kDa SNARE complex after antipsychotic treatment. International Journal of Neuropsychopharmacology 15, 573-588.
12. Han GA, Malintan NT, Collins BM, Meunier FA, et al. (2010). Munc18-1 as a key regulator of neurosecretion. Journal of Neurochemistry 115, 1-10.
13. Johnson RD, Oliver PL, Davies KE (2008). SNARE proteins and schizophrenia : linking synaptic and neurodevelopmental hypotheses. Acta Biochimica Polonica 55, 619-628.
14. Kim SH, Ryan TA (2010). CDK5 serves as a major control point in neurotransmitter release. Neuron 67, 797-809.
15. Kusakawa G, Saito T, Onuki R, Ishiguro K, et al. (2000). Calpain-dependent proteolytic cleavage of the p35 cyclin-dependent kinase 5 activator to p25. Journal of Biological Chemistry 275, 17166-17172. (Pubitemid 30398964)
16. Marek GJ, Behl B, Bespalov AY, Gross G, et al. (2010). Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia : too little juice or a miswired brain? Molecular Pharmacology 77, 317-326.
17. Nissen C, Holz J, Blechert J, Feige B (2010). Learning as a model for neural plasticity in major depression. Biological Psychiatry 68, 544-552.
18. Pandey GN, Dwivedi Y (2010). What can post-mortem studies tell us about the pathoetiology of suicide? Future Neurology 5, 701-720.
19. Ramos-Miguel A, Meana JJ, Garca-Sevilla JA (2011). The cdk5 cofactor p35 is reduced in schizophrenia postmortem brains : downregulation of cdk5/p35/p25 after antipsychotic medication. European Neuropsychopharmacology 21 (Suppl. 3), S507.
20. Rickman C, Duncan RR (2010). Munc18/Syntaxin interaction kinetics control secretory vesicle dynamics. Journal of Biological Chemistry 285, 3965-3972.
21. Shuang R, Zhang L, Fletcher A, Groblewski GE, et al. (1998). Regulation of Munc-18/syntaxin 1A interaction by cyclin-dependent kinase 5 in nerve endings. Journal of Biological Chemistry 273, 4957-4966. (Pubitemid 28108649)
22. Swatton JE, Sellers LA, Faull RL, Holland A, et al. (2004). Increased MAP kinase activity in Alzheimer's and Down syndrome but not in schizophrenia human brain. European Journal of Neuroscience 19, 2711-2719. (Pubitemid 38746388)
23. Tomizawa K, Ohta J, Matsushita M, Moriwaki A, et al. (2002). Cdk5/p35 regulates neurotransmitter release through phosphorylation and downregulation of P/Q-type voltagedependent calcium channel activity. Journal of Neuroscience 22, 2590-2597. (Pubitemid 37465808)
24. Tsai LH, Delalle I, Caviness Jr. VS, Chae T, et al. (1994). p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5. Nature 371, 419-423. (Pubitemid 24302556)
25. Urigu en L, Garca-Fuster MJ, Callado LF, Morentin B, et al 2009 Immunodensity and mRNA expression of A2A adenosine, D2 dopamine, and CB1 cannabinoid receptors in postmortem frontal cortex of subjects with schizophrenia : effect of antipsychotic treatment. Psychopharmacology 206 313-324.